Achieve Life Sciences, Inc. (ACHV) FinancialsACHVAchieve Life Sciences, Inc.

Evaluating the bottom line, Achieve Life Sciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -844.99%, provide a clear picture of how effectively ACHV converts its operational activities into shareholder value.

In the context of the broader market, ACHV competes directly with industry leaders such as ANNX and LXRX. With a market capitalization of $718.62M, it holds a significant position in the sector. When comparing efficiency, ACHV's gross margin of N/A stands against ANNX's N/A and LXRX's 94.36%. Such benchmarking helps identify whether Achieve Life Sciences, Inc. is trading at a premium or discount relative to its financial performance.

Achieve Life Sciences has faced significant losses, with a net income of -74,769,000 USD in Q2 2026 and a current ratio dropping to 0.95, indicating potential liquidity issues. However, the company has a strong pipeline with promising clinical trials for its Cytisinicline drug.